Amgen is attempting to expand into the CRC market with a cocktail of LUMAKRAS and VECTIBIX, however prior evidence indicates liver toxicity signals in Lung Cancer

Sotorasib in combination with panitumumab in refractory KRAS G12C mutated colorectal cancer: safety and efficacy for phase Ib full expansion cohort

Sep 08, 2022 | DelveInsight

LUMAKRAS (sotorasib) is being investigated in previously treated KRAS G12C-mutated CRC as monotherapy and in combination with other therapies. Presentation from Amgen at ESMO 2022 will feature safety and efficacy results from Phase Ib full expansion cohort, CodeBreaK 101 study, of LUMAKRAS in combination with VECTIBIX (panitumumab), in patients with KRAS G12C-mutated CRC. Data from this trial were previously featured at ESMO 2021. Which showed encouraging response rates that were much higher than the 9.7% response rate observed with LUMAKRAS monotherapy and highlighted the importance of combination therapy for patients with KRAS G12C-mutated advanced colorectal cancer. However, recently presented long-term efficacy and safety data from the CodeBreaK 100 Phase I/II trial in patients with KRAS G12C-mutated advanced NSCLC who received LUMAKRAS in combination with PD-(L)1 inhibitor at the 2022 World Conference on Lung Cancer (WCLC) raised questions about elevated liver toxicity and a lackluster response rate. Despite the liver toxicity warning, it will be fascinating to see if Amgen still believes it has a viable answer to the problem. Mirati appears to have an edge in late-line colorectal cancer patients with a KRAS G12C mutation, based on available clinical findings.

Date: 12/9/2022 from 10:25 AM to 10:35 AM

Abstract Type: Proffered Paper session

Abstract No.: 315O

Featured Companies: Amgen, Roche, Mirati Therapeutics, Moderna therapeutics/ Merck,  Eli Lilly and Company, Loxo Oncology, Boehringer Ingelheim, Biomea Fusion, Seagen, Bayer, Taiho Pharma, SurgiMAb, Celleron Therapeutics, and others

Recent Article